Evaluating a new treatment for resectable gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, multicenter, open-label phase II study aimed at assessing the effectiveness and safety of a combination therapy involving tislelizumab, oxaliplatin, capecitabine, and PLD in patients with resectable stage III gastric adenocarcinoma. Participants will receive the treatment for 2 to 4 cycles before undergoing radical surgical resection. Radiological evaluations will be conducted every two cycles to determine tumor resectability, and patients will be followed for survival outcomes post-surgery until they withdraw consent, are lost to follow-up, or pass away.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age: 18\~75 years old.
2. Karnofsky Performance Status Score ≥70.
3. Histological or cytological diagnosed as gastric adenocarcinoma, HER2-, PD-1/L1+.
4. Clinical stage stage III (8th edition of the AJCC Cancer Staging Manual).
5. Physical condition and organ function allow for larger abdominal surgery.
6. Subject baseline blood routine and biochemical indicators meet the following standards: hemoglobin ≥90g/L; absolute neutrophil count (ANC) ≥1.5×10\^9g/L; platelets counts (PLT) ≥100×10\^9/L; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤2.5 times the upper limit of normal (ULN); serum total bilirubin \<1.5 ULN; serum creatinine \<1 ULN; serum albumin ≥30g/L.
7. Heart function:

   1. Left ventricular ejection fraction (LVEF) ≥50%;
   2. 12-ECG indicates no myocardial ischemia;
   3. No history of arrhythmia requiring drug intervention before enrollment;
8. No serious concomitant diseases that make the survival time \< 5 years.
9. Agree and be able to comply with the protocol during the study period.
10. Provide written informed consent before entering the study.

Exclusion Criteria:

1. Received chemotherapy, radiotherapy or immunotherapy for this gastric cancer.
2. Pregnant or breastfeeding women.
3. Women of childbearing age who had a positive pregnancy test at baseline or who did not have a pregnancy test. Menopausal women must have menopause for at least 12 months before they can become pregnant.
4. Men and women who are sexually active (possible to have children) are unwilling to use contraception during the study period.
5. Patients with mass ascites and positive abdominal free cancer cells.
6. With a history of other malignancies in the last 5 years, except for cured non-melanoma skin cancer and cervical carcinoma in situ.
7. With a history of epilepsy, central nervous system disease, or mental disorder may be judged by the investigator that their clinical severity may hinder the signing of informed consent or affect the patient's oral medication compliance.
8. Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) grade II or more severe congestive heart failure, or severe arrhythmia requiring medical intervention, or the last 12 There was a history of myocardial infarction within months.
9. Patients deficiency of dihydropyrimidine dehydrogenase (DPD).
10. Peripheral nerve disease ≥ NCI CTC AE grade 2. However, the patients only with deep tendon reflex (DTR) disappears do not need to be excluded.
11. Organ transplantation requires immunosuppressive therapy.
12. Severe uncontrolled repeated infections, or other serious uncontrolled concomitant diseases.
13. Moderate or severe renal damage \[creatinine clearance ≤50ml/min (calculated according to Cockroft and Gault equation), or serum creatinine\> ULN\].
14. Acute or chronic active hepatitis B, hepatitis C infection, hepatitis B virus (HBV) DNA\>2000IU/ml or 10\^4 copies/ml, hepatitis C virus (HCV) RNA\>10\^3 copies/ml, hepatitis B surface antigen (HbsAg) is positive at the same time as anti-HCV antibody.
15. Allergic to any research drug ingredients.
16. Participating in other trials within 4 weeks before enrollment.
17. Not suitable to participate in this trial for any reason judged by the investigator.

Where it's running

• Shanghai General Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Qi Li, Prof.
• Email: Leeqi2001@hotmail.com
• Phone: 13818207333

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tislelizumab with FOLFOX versus POF for unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma

  This trial tests whether adding the immunotherapy drug tislelizumab to FOLFOX works better than adding it to POF for adults with unresectable or metastatic stomach or gastroesophageal junction cancer whose tumors have CPS≥1.

  Recruiting Phase 3 Fujian Cancer Hospital · Fuzhou, Fujian · NCT06793917

• Combination treatment for advanced gastric cancer with HER2 overexpression

  This study is testing a new combination treatment for patients with advanced gastric cancer that has high levels of HER2 to see if it can improve their outcomes.

  Recruiting at 2 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT06560528

• Combination treatment for advanced gastric cancer with specific biomarkers

  This study is testing a new combination treatment for people with advanced gastric cancer who have certain biomarkers to see if it helps them live longer without their disease getting worse.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06157996

• Testing BAL0891 for advanced solid tumors and acute myeloid leukemia

  This study is testing a new treatment called BAL0891 to see if it can safely help people with advanced solid tumors or acute myeloid leukemia.

  Recruiting at 15 sites Phase 1 SillaJen, Inc. · New Haven, Connecticut and 16 other locations · NCT05768932

• Tislelizumab combined with chemoradiotherapy for advanced gastric cancer

  This study is testing if combining the immunotherapy drug Tislelizumab with chemoradiotherapy can help people with advanced stomach cancer do better before or after surgery compared to standard treatments.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Wuhan, Hubei and 2 other locations · NCT05687357

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.